Pricing Log in Create free account
Friday 6 November 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.

Revenue
−0.28%
EPS
−154.6%
Free cash flow
+38.8%
Total debt
−89.4%

Quarter to September 2026, against a year earlier

19.67 0.70 +3.69%
Market cap
$21.8B
P/E
0.0×
Fwd P/E
82.6×
Dividend yield
2.54%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Viatris Inc. 10-Q filed Nov 5, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 9:23 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 6, 2026: 10 added · 6 removed · 51 modified; 34 with only figures updated

  1. Modified

    This discussion and analysis should be read in conjunction with the Consolidated Financial Statements, the related Notes to Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Viatris’ 2025 Form 10-K, the unaudited interim financial statements and related Notes included in Part I — Item 1 of this Form 10-Q and our other SEC filings and public disclosures. The interim results of operations and comprehensive (loss) earnings for the three and sixnine months ended JuneSeptember 30, 2026, and cash flows for the sixnine months ended JuneSeptember 30, 2026 are not necessarily indicative of the results to be expected for the full fiscal year or any other future period.

66 more changes in this Item, word by word, in Powerpack.